Boehringer Ingelheim International GmbH / Abexxa Biologics Inc.

Solid tumors (TCR-mimetic antibodies targeting intracellular tumor antigens)

1.8M US cases/yr · $35.0B Global cancer immunotherapy market 2024 (USD MM) · 611720 US cancer deaths annually

Disease Overview

Solid tumors (breast, lung, prostate, colorectal, ovarian, pancreatic, melanoma, head and neck and others) account for approximately 90% of US cancer incidence — about 1.8 million of the ACS-projected 2.0 million new cancer diagnoses in 2024 — and roughly 80% of cancer deaths annually. Existing immunotherapies (anti-PD-1/PD-L1 checkpoint inhibitors Keytruda, Opdivo, Tecentriq, Imfinzi, Libtayo; anti-CTLA-4 Yervoy; LAG-3 Opdualag; bispecifics Tecvayli, Talvey, Imdelltra) target surface receptors and immune checkpoints, but do not directly engage the ~80-90% of tumor-specific proteins (oncoproteins like MAGE, NY-ESO-1, WT1, KRAS, p53, AFP) that reside intracellularly. These antigens are presented as peptide-HLA complexes on the cell surface and have historically been addressable only through engineered T-cell receptor (TCR) therapies (Adaptimmune afami-cel/Tecelra approved Aug 2024; Immunocore tebentafusp/Kimmtrak approved Jan 2022 for uveal melanoma). TCR-mimetic antibodies represent a competing modality — conventional antibodies engineered to recognize peptide-HLA complexes the way a TCR does — with potential advantages in manufacturability and dosing relative to autologous TCR-T cell therapies. Boehringer Ingelheim's strategy is to combine its existing T-cell engager and oncolytic virus platforms (Vsiv) with the Abexxa TCR-mimetic platform, creating multi-modal regimens that hit both surface and intracellular cancer antigens.

Competitive Landscape

Direct competitors at deal date in TCR-mimetic / peptide-HLA antibody space were limited and almost entirely preclinical or early-Phase 1: Eureka Therapeutics' ARTEMIS T-cell platform (ET140203 in HCC, ET190L1 in B-cell), Adaptimmune's TCR-T platform (afami-cel in synovial sarcoma, Phase 2 SPEARHEAD-1; later Tecelra approval Aug 2024), Immunocore (tebentafusp/Kimmtrak in uveal melanoma, BLA filed Q3 2021, approved Jan 2022 — a bispecific TCR-CD3 ImmTAC), Medigene (TCR pipeline), GT Biopharmaceuticals and Lion TCR. NKG2A:HLA-E checkpoint axis competitors at deal date: Innate Pharma/AstraZeneca monalizumab (Phase 3 INTERLINK-1 in head and neck cancer, missed primary endpoint Q3 2022), Tizona Therapeutics TZN-1043 (preclinical), and Boehringer's own oncology pipeline including BI 836880 (anti-VEGF/Ang2 nanobody) and BI 765063 (anti-SIRPα, partnered with OSE Immunotherapeutics). Big Pharma cancer immunology platforms include Roche, BMS, Merck, AstraZeneca, Pfizer (Trillium acquisition Aug 2021), Sanofi, Gilead/Kite, J&J, Novartis. Boehringer's broader oncology portfolio added Zongertinib (HER2 TKI, FDA approval Aug 2025) and Brigimadlin (MDM2 inhibitor, Phase 3 dedifferentiated liposarcoma).